India Launches National Mass Drug Administration Campaign to Eliminate Lymphatic Filariasis

India -Launches -National -Mass -Drug- Administration -Campaign- to- Eliminate -Lymphatic -Filariasis
Photo credits: maxhealthcare.in

Nationwide Drive to Combat Lymphatic Filariasis by 2027

Union Health Minister JP Nadda has launched the annual national mass drug administration (MDA) campaign to eliminate Lymphatic Filariasis (LF) by 2027. The initiative targets 13 identified LF-endemic states.

Free Medicines for Over 17.5 Crore People

The Health Minister, during a virtual launch, announced that starting February 10, free medicines will be distributed across endemic districts. He urged residents in these areas to consume the medication to protect themselves and their families from this debilitating disease.

Targeting Over 90% of Eligible Population

Minister Nadda emphasized the need for endemic districts to ensure that more than 90% of the eligible population takes anti-filaria medicines. He reaffirmed India’s commitment to eliminating LF by 2027, well ahead of the Sustainable Development Goal (SDG) target of 2030.

Coverage Across 13 States

The MDA campaign will reach 111 endemic districts across 13 states:

  • Andhra Pradesh
  • Assam
  • Bihar
  • Chhattisgarh
  • Gujarat
  • Jharkhand
  • Karnataka
  • Kerala
  • Madhya Pradesh
  • Maharashtra
  • Odisha
  • Uttar Pradesh
  • West Bengal
Also Read |  Advancing Fertility Care: Key Insights from Nova IVF’s ART Conference

Drug Regimen for LF Patients

Authorities will administer the following medications free of cost:

  • Double Drug Regimen: Diethylcarbamazine Citrate (DEC) and Albendazole.
  • Triple Drug Regimen: Ivermectin, DEC, and Albendazole.

Lymphatic Filariasis: A Major Public Health Concern

Commonly known as elephantiasis, Lymphatic Filariasis (Haatipaon) remains a priority disease in India. It has been reported in 345 districts across 20 states and union territories, with 90% of cases concentrated in eight states.

Current LF Case Statistics

According to the National Centre for Vector Borne Diseases Control Board, by 2023, India reported:

  • 6.19 lakh cases of lymphedema
  • 1.26 lakh cases of hydrocele

As reported by economictimes, these cases have emerged from all endemic districts, underscoring the urgency of this nationwide campaign.

By ensuring widespread participation and adherence, India is on track to eliminate LF, improving public health and quality of life for millions.